Ionis Pharmaceuticals (IONS) Stock: Here’s What You Need To Know

Ionis Pharmaceuticals (NASDAQ:IONS) After the market closed on December 23, Ionis had announced that it had received FDA approval, together with Biogen, for its Spinal Muscular Atrophy drug. This drug, known as Spinraza, was developed by both companies to treat patients with Spinal Muscular Atrophy (SMA), a rare-genetic disorder. This was a huge surprise because … Read more

Clovis Oncology (CLVS) Stock: The Low Down On Approval

Clovis Oncology (NASDAQ:CLVS) On Monday, Clovis Oncology stock closed higher by 9% after it announced that the FDA had approved its drug. The drug in question is known as rucaparib – to be marketed as Rubraca. This was for early approval of rucaparib, which is used to treat patients with advanced ovarian cancer. The stock … Read more

Arrowhead Pharmaceuticals (ARWR) Stock: Here’s What You Need To Know

Arrowhead Pharmaceuticals (NASDAQ:ARWR) On Monday, Arrowhead Pharmaceuticals stock closed down by 1.58%, even though it announced that it had completely finished the deal with Amgen. The deal between Arrowhead and Amgen had finally closed today. Investors weren’t too enthusiastic, as the stock closed lower instead of heading higher. This news is definitely good news, and … Read more

Dynavax Technologies (DVAX) Stock: Here’s What You Need To Know

Dynavax Technologies (NASDAQ:DVAX) On Monday, Dynavax Technologies stock closed the day lower by 64.55% after the company announced that the FDA has rejected Hepislav-B, its lead vaccine product. This product is being used to treat patients with the Hepatitis B virus. Not many treatment options are available to those with the Hepatitis B virus, therefore … Read more

Inovio (INO) Stock: Here’s What You Need To Know

Inovio Pharmaceuticals (NASDAQ:INO) On Monday, Inovio Pharmaceuticals closed the day down by 17% after the company announced that the FDA had placed its trial initiation on hold. This refers to the phase 3 clinical trial that was supposed to begin shortly treating women with cervical dysplasia or CIN 2/3 lesions. The vaccine to be used … Read more

PTC Therapeutics (PTCT) Stock: Here’s What You Need To Know

PTC Therapeutics (NASDAQ:PTCT) On Monday, PTC Therapeutics fell by 40% to $7.97 per share after the company had announced that the FDA refused its appeal for a refuse-to-file letter. PTC Therapeutics has not been able to get the FDA to back its Duchenne Muscular Dystrophy — DMD — drug. What happened was that PTC had … Read more

Durect Corp (DRRX) Stock: Here’s What You Need To Know

Durect Corp. (NASDAQ:DRRX) On Monday, Durect Corp stock fell by 32% after Pain Therapeutics (PTIE) received a Complete Response Letter — CRL — from the Food and Drug Administration — FDA. The drug that received the CRL is known as Remoxy ER, and was Pain’s drug obtained through a license from Durect Corp. The FDA … Read more

Sarepta Therapeutics (SRPT) Stock: Here’s What You Need To Know

Sarepta Therapeutics (NASDAQ:SRPT) On Monday, Sarepta’s stock closed the day up 73.85% after the company announced that the FDA had given its drug Eteplirsen FDA approval. More specifically, the company filed for accelerated approval. In other words, drugs can be approved after only completing a phase 2 study if the results show that a surrogate … Read more

Arena Pharmaceuticals (ARNA) Stock: Here’s What You Need To Know

Arena Pharmaceuticals (NASDAQ:ARNA) Arena Pharmaceuticals has been struggling to stay afloat as a company, especially with Belviq under performing in the obesity market. Thing are about to get worse because now it will have to go back to the drawing board. In other words, it has admitted that Belviq is not taking off in the … Read more

Aurinia Pharmaceuticals (AUPH) Stock: Here’s What You Need To Know

About a week ago Aurinia Pharmaceuticals cratered by 55.75% to close at $1.81 per share. The ironic thing is that the company had announced positive phase 2 results in patients with Lupus Nephritis. If the company posted positive phase 2b results in this patient population then why did the share price tank by so much? … Read more